Treatment of chronic inflammatory diseases with implantable medical devices

Cleveland Clinic Journal of Medicine

Volumn 78, Issue SUPPL. 1, 2011, Pages

  Zitnik, Ralph J ^a  

^a SetPoint Medical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867151480     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78.s1.05     Document Type: Article

References (26)

1. Bristow MR, Saxon LA, Boehmer J, et al. Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defi brillator in advanced chronic heart failure. N Engl J Med 2004; 350:2140-2150.
2. Van Maanen MA, Vervoordeldonk MJ, Tak PP. The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis. Nat Rev Rheumatol 2009; 5:229-232.
3. Tracey KJ. Reflex control of immunity. Nat Rev Immunol 2009; 9:418-428.
4. Borovikova LV, Ivanova S, Zhang M, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405:458-462.
5. Huston JM, Ochani M, Rosas-Ballina M, et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203:1623-1628.
6. Rosas-Ballina M, Ochani M, Parrish WR, et al. Splenic nerve is required for cholinergic antiinflammtory pathway control of TNF in endotoxemia. Proc Natl Acad Sci 2008; 105:11008-11013.
7. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003; 421:384-388.
8. Wang H, Liao H, Ochani M, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004; 10:1216-1221.
9. De Jonge WJ, Van Der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005; 6:844-851.
10. Huston JM, Rosas-Ballina M, Xue X, et al. Cholinergic neural signals to the spleen down-regulate leukocyte trafficking via CD11b. J Immunol 2009; 183:552-559.
11. O'Mahony C, Van Der Kleij H, Bienenstock J, et al. Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. Am J Physiol Regul Integr Comp Physiol 2009; 297:R1118-R1126.
12. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, et al. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 2006; 131:1122-1130.
13. Ghia JE, Blennerhassett P, Collins SM. Vagus nerve integrity and experimental colitis. Am J Physiol Gastrointest Liver Physiol 2007; 293:G560-G567.
14. Karimi K, Bienenstock J, Wang L, et al. The vagus nerve modulates CD4+ T cell activity. Brain Behav Immun 2010; 24:316-323.
15. Huston JM, Gallowitsch-Puerta M, Ochani M, et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 2007; 35:2762-2768.
16. Levine Y, Faltys M, Black K, et al. Neurostimulation of the cholinergic anti-inflammatory pathway (NCAP) ameliorates CIA in rats. Ann Rheum Dis 2010; 69(suppl 3):191.
17. Zhang Y, Popovic ZB, Bibevski S, et al. Chronic vagus nerve stimulation improves autonomic control and attenuates systemic inflammation and heart failure progression in a canine high-rate pacing model. Circ Heart Fail 2009; 2:692-699.
18. Gupta RC, Imai M, Jiang AJ, et al. Chronic therapy with selective vagus nerve stimulation normalizes plasma concentration of tumor necrosis factor alpha, interleukin-6, and B-type natriuretic peptide in dogs with heart failure. J Am Coll Cardiol 2006; 47:77A.
19. Beekwilder JP, Beems T. Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol 2010; 27:130-138.
20. Ben-Menachem E. Vagus nerve stimulation, side effects, and longterm safety. J Clin Neurophysiol 2001; 18:415-418.
21. Heck C, Helmers SL, DeGiorgio CM. Vagus nerve stimulation therapy, epilepsy, and device parameters: scientific basis and recommendations for use. Neurology 2002; 59(6 suppl 4):S31-S37.
22. Huikuri HV, Jokinen V, Syvänne M, et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19:1979-1985.
23. Sajadieh A, Nielsen OW, Rasmussen V, et al. Increased heart rate and reduced heart-rate variability are associated with subclinical inflammation in middle-aged and elderly subjects with no apparent heart disease. Eur Heart J 2004; 25:363-370.
24. Louthrenoo W, Ruttanaumpawan P, Aramrattana A, et al. Cardiovascular autonomic nervous system dysfunction in patients with rheumatoid arthritis and systemic lupus erythematosus. QJM 1999; 92:97-102.
25. Evrengül H, Dursunoglu D, Cobankara V, et al. Heart rate variability in patients with rheumatoid arthritis. Rheumatol Int 2004; 24:198-202.
26. Stojanovich L, Milovanovich B, De Luka SR, et al. Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases. Lupus 2007; 16:181-185.